Opioid 'Data Warehouse' Is Part Of US FDA's New Controlled Substances Program

 
• By Derrick Gingery

CDER-based program lead by Marta Sokolowska will also handle benzodiazepine and stimulants activities and consult on relevant application assessments.

An ampoule Opioid next to it is a note written in English Opioid epidemic. All around, many tablets and syringes are scattered.
The FDA's new opioid data warehouse, intended to collect data related to the crisis and inform regulatory change, also will come under the CSP purview. • Source: Shutterstock

More from US FDA

More from Agency Leadership